Alzheimer’s drug slows progression, new study shows

CNN --

Drug makers Biogen and Eisai state that a monoclonal antibody treatment for Alzheimer's disease slowed the progression of cognitive decline by 27%.

The drug, lecanemab, was tested in a phase 3 global clinical trial. Lecanemab showed positive effects on the patient's cognition and the ability to perform everyday tasks as compared to a placebo.

Both companies plan to publish their findings in a peer-reviewed journal and present the data in order to seek approval from U.S. regulators. The Alzheimer's Association has expressed hope over the results.